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Abstract—The quick dynamic insulin sensitivity test (DISTq) can yield an insulin sensitivity result immediately after a 30-minute clinical protocol. The test uses intravenous boluses of 10g glucose and 1U insulin at t=1 and 11 minutes, respectively, and measures glucose levels in samples taken at t=0, 10, 20 and 30 minutes. The low clinical cost of the protocol is enabled via robust model formulation and a series of population-derived relationships that estimate insulin pharmacokinetics as a function of insulin sensitivity (SI). 
50 individuals underwent the gold standard euglycaemic clamp (EIC) and DISTq within an 8-day period. SI values from the EIC and two DISTq variants (4-sample DISTq and 2-sample DISTq30) were compared with correlation, Bland-Altman and receiver operator curve analyses.
DISTq and DISTq30 correlated well with the EIC (R=0.76 and 0.75, and ROC c-index=0.84 and 0.85, respectively). The median differences between EIC and DISTq/DISTq30 SI values were 13% and 22% respectively.
The DISTq estimation method predicted individual insulin responses without specific insulin assays with relative accuracy and thus high equivalence to EIC SI values was achieved. DISTq produced very inexpensive, relatively accurate immediate results, and can thus enable a number of applications that are impossible with established SI tests.  
Index Terms— a-posterirori parameter identification, insulin sensitivity, parameter identification, structural model identifiability, 
I.	INTRODUCTION
I
NSULIN sensitivity (SI) is an important metabolic characteristic that can indicate the risk of developing type 2 diabetes, cardiovascular disease and the metabolic syndrome  ADDIN EN.CITE []. Established insulin sensitivity tests are either low intensity and low accuracy, or high intensity with improved accuracy. SI can be measured in vivo using several different types of clinical tests  ADDIN EN.CITE [, ]. Dynamic tests that use bolus stimuli of glucose, and sometimes insulin, are often undertaken to yield data that is assessed for model based metrics of insulin sensitivity. The Minimal Model of insulin/glucose pharmacodynamics has been used extensively to model patient responses to measured blood glucose and insulin samples  ADDIN EN.CITE []. However, the concurrent identification of SI and glucose sensitivity (SG) terms in the Minimal Model becomes practically non-identifiable  ADDIN EN.CITE [, ] in some clinically relevant cohorts  ADDIN EN.CITE [, , ], despite the theoretical structural identifiability of the model  ADDIN EN.CITE []. 
The limited practical identifiability of the model despite theoretical identifiability [] has led to an increase in protocol duration and sampling frequency with the aim of gaining sufficient data to increase error surface convexity. Increased error surface convexity typically enables more effective parameter identification []. In some cases, protocol duration has extended up to 5 hours  ADDIN EN.CITE [, ]. Bayesian methods have also been used to improve results, but limit the influence of the patient-specific response to the test stimulus in the identified value and negate the uniqueness of the identified model parameters. Furthermore, the sensitivity to glucose (SG) term has limited clinical value in comparison to the insulin sensitivity term  ADDIN EN.CITE [, ] and may obscure the strength of the patient–specific data signal  ADDIN EN.CITE [, ]. 
Prior work hypothesised that by setting the SG term to a population constant [, ] and identifying SI only, model structural identifiability would be improved. Hence, protocol duration, clinical intensity and cost could be reduced. Preliminary studies of the quick dynamic insulin sensitivity test (DISTq) have shown that fixing SG could improve model identifiability to an extent that would eliminate the need for insulin and C-peptide assays  ADDIN EN.CITE []. Insulin and C-peptide assays account for a significant proportion of the clinical cost of the test, and are the only aspect of the protocol that cannot be undertaken at the bedside. Hence, if the findings of these preliminary studies were clinically validated, the DISTq could be proposed as a low-cost SI test with the unique ability to yield results immediately after the test.
In this investigation, DISTq SI values from 50 individuals are compared to SI values obtained by the gold standard euglycaemic clamp (EIC) method []. Two DISTq variants are tested. A 4-sample DISTq and a version that only uses the initial and final glucose samples (DISTq30) [].
II.	Methods
Data for this study was gathered during the validation of the dynamic insulin sensitivity and secretion test (DISST) [].
A.	Participants
Fifty Participants (25M/25F) from the Canterbury region of New Zealand were recruited via newspaper advertisements and flyers posted on notice boards at Christchurch Hospital and Canterbury University. Ten lean (BMI≤25), 20 overweight (25<BMI≤30) and 20 obese (BMI>30) participants were recruited. Each category had an even gender distribution. The median BMI of the cohort was 28.6 kg·m-2 (IQR: 25.9 to 33.0, range: 19.0 to 64.9) and the median age was 41 (IQR: 29 to 49, range: 20 to 69). Participants were excluded if they had any major physical or psychological illness, including type 1 or type 2 diabetes. Approval for this study was granted by the Upper South Island Regional Ethics Committee B and all participants signed informed consent prior to any tests.
B.	Clinical test protocols
Participants underwent EIC, DISST and oral glucose tolerance test (OGTT) protocols within an eight day period in a randomised order. All tests began at 9am after a 12 hour fast and were undertaken at the endocrine test centre of the Christchurch Hospital. Participants were weighed and had their height measured prior to their first test. All participants sat in a supine position for the duration of the tests.
1)	Euglycemic hyperinsulinaemic clamp (EIC)
The EIC was undertaken according to the method described by Ferrannini and Mari []. Insulin (actrapid, Novo Nordisk) and glucose (25% dextrose) was infused into the participant via a cannula in the antecubtial fossa. Insulin was infused at 40 mU·m-2·min-1 to obtain a target plasma insulin concentration of 100 mU·L-1. Blood samples were taken at 5 minute intervals via a cannula that was placed retrograde in the dorsum of the hand. The participants hand was placed in a purpose built heated hand box. Glucose levels in the samples were measured at the bedside to allow the clinician to maintain euglycaemia by modulating the glucose infusion rate. Samples at t=60, 80, 100, and 120 minutes were assayed for insulin.
2)	Dynamic insulin sensitivity and secretion test (DISST)
Participants had a catheter inserted in their antecubital fossa. A 10 g glucose bolus (50% dextrose) was administered via the catheter at t = 1 minutes and a 1 U insulin bolus (actrapid, Novo nordisk) was administered at t = 11 minutes. Blood was sampled from the catheter immediately before the glucose and insulin assays (t = 0, and 10 minutes), and at t = 5, 20 and 30 minutes. Blood concentrations of glucose, insulin and C-peptide were measured. DISTq and DISTq30 did not use insulin or C-peptide data. The DISTq parameter identification method ignored the t = 5 minute glucose measurement, and DISTq 30 ignored the t = 5, 9 and 20 minute measurements.
3)	Oral glucose tolerance test (OGTT)
Participants drank a lightly carbonated drink with 75 g glucose content at t = 1 minute. Blood samples obtained via a catheter in the antecubtial fossa were assayed for glucose and insulin at t = 0, 30, 60 and 120 minutes.
C.	Assay methods
Glucose was measured in whole blood using the YSI 2300 stat plus Glucose and L-Lactate analyser (YSI incorporated, Yellow Springs, Ohio). Insulin and C-peptide levels were determined at Endolab, Canterbury Health Laboratories, via Roche Elecsys® after PEG precipitation of immunoglobulins (Roche Diagnostics, Mannheim, Germany). 
D.	Parameter identification
1)	Euglycemic hyperinsulinaemic clamp (EIC)
SI values from the EIC were calculated using an average of the glucose infusion rate over the final 40 minutes of the clamp protocol and the mean value of the plasma insulin measurements. A space correction term (SC) was introduced to model any slight transients in the measured glucose during the final 40 minutes.
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where: ISI is EIC SI index (10-2 mg∙L∙(kg∙pmol∙min)-1);  is the average glucose infusion rate over the final 40 minutes of the EIC (mg∙min-1);  is the mean plasma insulin level over the final 40 minutes of the EIC (pmol∙L-1); BW is the subject’s body weight (kg) and ΔG is the change in glucose across the final 40 minutes of the test (mmol∙L-1).
2)	Quick DIST (DISTq)
DISTq uses glucose measurements from the DISST protocol, but not insulin or C-peptide measurements. This study examines a 4-sample DISTq and a less clinically intense 2-sample DISTq30 protocol. Insulin responses to test stimulus are estimated via a series of population based relationships between SI and key insulin pharmacokinetic parameters. Hence, DISTq parameter identification requires a relatively computationally intense iterative a-posteriori method. To make the method accessible to all groups, a stand-alone DISTq parameter identification program has been developed and is freely available upon request to the authors. Figure 1 shows the DISTq parameter identification methodology. 
Step 1. An arbitrary insulin sensitivity value is chosen to enable an initial estimation of the participant’s insulin pharmacokinetic rate parameters. The identified insulin sensitivity value is not sensitive to the choice of starting value [].
Step 2. Equations 3-7 define the relationships between the insulin sensitivity and insulin pharmacokinetic parameters. These equations were developed using an isolated cohort (N=46) []. The isolated cohort was also from New Zealand and had a similar broad range of physiological characteristics to the fifty participants of this study (median BMI 25.5 kg·m-2, IQR 24.0 to 33.4, range 19.5 to 41.3). The insulin and C-peptide data obtained during this investigation was not used to generate Equations 3-7 were not influenced by any insulin or C-peptide data gathered in the clinical trial []. 









where: nL is the insulin clearance rate (min-1), I0 is the basal plasma insulin concentration (pmol.L-1), UN,t is the endogenous insulin production profile (pmol·L-1·min-1) and insulin sensitivity is given in units of (x10-4 mU·L-1·min-1). Endogenous insulin is calculated at 1-minute resolution in the algorithm, but is only shown here at t = 0, 5 and 20 for brevity.
Step 3. The insulin pharmacokinetic parameters defined in step 2 are used to simulate an interstitial insulin profile using Equations 8 and 9:
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where: nK, nI, and nC, are rate parameters (min-1 or L·min-1, a-priori); αI is the saturation coefficient of liver clearance (L·pmol-1, a-priori); I and Q are plasma and interstitial compartment insulin concentrations (pmol·L-1, simulated); UX and PX are the insulin and glucose bolus inputs (pmol·min-1 and mmol·min-1, respectively, a-priori); VP and VQ are volumes of distribution (L, a-priori); xL is the fractional first pass liver extraction (dimensionless, a-priori); 
Step 4. The iterative integral method [] is used to minimise the squared error between the measured glucose data and the glucose profile simulated by Equation 10. The t=5 glucose data point is not used due to potentially deleterious effects of un-modelled mixing. The interstitial insulin profile from Step 3 is used as model input. While DISTq identifies both SI and VG as patient-specific model variables, DISTq30 identifies only SI and estimates VG as 29% of lean body mass [, ].
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where: G is the glucose concentration in the plasma (mmol·L-1, simulated); pG is a rate parameter (min-1); VG is the distribution volume of glucose (L, identified in DISTq, a-priori in DISTq30); SI is the insulin sensitivity  (L·pmol-1·min-1, identified); and GB and QB are basal levels of each respective species.
Step 5. The SI value is checked for convergence. If the change in the identified SI value are greater than 0.1% the insulin pharmacokinetic parameters are re-assessed and steps 2-4 are repeated. Typically, less than 10 iterations are required and parameter identification can be undertaken in less than a second. SI is considered converged once changes between iterations are less than 0.1%.
Insulin sensitivity values from DISTq are calibrated to gain unit-equivalence to the EIC and allow a direct comparison in terms of magnitude:
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where: γ=0.5 is the steady state ratio between plasma insulin and interstitial insulin [].
3)	OGTT
In this study, the OGTT was used to define the participant’s diabetic status. The American Diabetes Association (ADA) criteria for diabetes diagnosis requires repeated 2 hour glucose measurement of >11.0 mmol·L-1 for a diagnosis of diabetes []. The ADA criteria state that a 2 hr glucose >7.8 mmol·L-1 can be used to diagnose impaired glucose tolerance [].
The Matsuda index [] and HOMA2 scores [] were calculated from glucose and insulin measurements taken during the OGTT. 
E.	Statistical analysis
Equivalence between the DISTq and EIC was assessed via correlation analysis, Bland-Altman plots, and receiver operator curves (ROC). The ROC curve for the EIC comparison used an arbitrary cut-off value of ISIEIC=1×10-2 mg∙L∙kg-1∙pmol-1∙min-1, which was approximately the median ISI score recorded by the clamp in the cohort. Thus, given the relatively high rate of obesity in the cohort (40%), this median ISI may also represent a threshold of elevated metabolic risk  ADDIN EN.CITE [, , ] providing a further assessment of potential clinical utility. The ROC c-unit was defined as the area under the ROC curve.
III.	Results
DISTq and DISTq30 ISI values correlated to the EIC values at R=0.76 and R=0.75, respectively. The Bland-Altman analysis produced a median DISTq and DISTq30 over-estimation of the EIC of 13.4% (IQR -24.7 to 33.1%) and 22.7% (IQR -17.4 to 41.4%), respectively. The ROC c-units were 0.84 and 0.85, respectively. Figure 2 shows the correlation, Bland-Altman and ROC curves for DISTq and DISTq30. DISTq and DISTq30 correlated at R=0.84 and R=0.86, respectively to the fully sampled DISST. 
There were no cases of symptomatic hypoglycaemia during the DISST protocol, and participant acceptance was high. According to the American Diabetes Association (ADA) criteria for diagnosis of diabetes, one participant met the criteria for diabetes on the basis of the 2hr OGTT glucose measurement, although formal diagnosis would require a second test, and four individuals had impaired glucose tolerance. 
Figure 2. Correlations (left), proportional Bland-Altman plots (centre) and ROC curves (right) between the ISI values [10-2 mg∙L∙kg-1∙pmol-1∙min-1] of the DISTq and the EIC (top) and DISTq30 and the EIC (bottom). The correlation plots show the 1:1 line (∙ ∙ ∙) and the Bland-Altman plots show the median and quartiles (∙ ∙ ∙) of the proportional differences in ISI.
It was noted that a single participant had an irregular endogenous insulin production response to the DISST test glucose stimulus, contributing to a disproportionate effect on the correlation and ROC analysis. By self-report this individual consumed large quantities of sugary ‘energy’ drinks (>1L/day). The first phase insulin response of this participant (2.8U) was significantly higher than the upper quartile of first-phase responses (1.10U). Omitting data from this participant changed the correlation to R=0.78 for DISTq and R=0.80 for DISTq30, and the ROC c-units became 0.88 and 0.89, respectively.
In this study, HOMA2 values correlated to the EIC at R=0.60 (ROC c-unit=0.92) and the Matsuda index correlated to the EIC at R=0.74 (ROC c-unit=0.95).
IV.	Discussion
Formulating the model of glucose and insulin dynamics such that a single model variable is used to define glucose clearance allows DISTq much greater practical model identifiability than the Minimal Model. Model identifiability was improved to the extent that SI values with a high correlation to the gold standard EIC were measured using only 2-4 glucose measurements from a relatively low-intensity 30-minute clinical protocol. In contrast, the Minimal Model requires a 2-3 hour IVGTT or insulin modified IVGTT test with 10+ glucose and insulin assays to report similar gold standard SI correlations  ADDIN EN.CITE []. These results confirm the hypothesis in Docherty et al. [].
Figure 2 shows that DISTq SI and EIC values had a minimal and non-systemic bias. In data not shown, the correlation between EIC and DISTq is approximately unchanged if the DISTq process is not iterated (i.e. insulin parameters are constant across the cohort and are not a function of SI). However, the bias then becomes systemic. Insulin resistant participants have a tendency toward lower insulin clearance rates (Equation 3, []). Hence, if a population value for nL were used to model an insulin resistant populations test response, their plasma insulin concentrations would be underestimated. Subsequently, SI would be overestimated. The inverse is true for insulin sensitive participants. In confirmation, Yates et al. found systemic bias when using a similar methodology without iterative estimation of insulin kinetics [].  Hence the improved results and lack of systemic bias are a function of the modelling and identification methods.
The high correlation and limited bias between the DISTq and EIC SI values implies that the DISTq would be a suitable EIC surrogate when low-cost or immediate results are desired. In addition, the EIC protocol generates a steady-state, supra-physiological insulin concentration. In contrast, DISTq uses a low-dose insulin bolus to achieve dynamic, physiological insulin excursions. The supra-physiological insulin concentration of the EIC is less efficient due to saturation of insulin action  ADDIN EN.CITE [, ]. Hence, the DISTq over-estimation of EIC SI values may be expected due to saturation effects that are known to affect EIC outcomes  ADDIN EN.CITE [, ]. The 30 minute 2-4 sample DISTq protocol is considerably less clinically intense than the 3-4 hour, 24-30 sample gold-standard EIC test. However, DISTq lacks some of the repeatability of the EIC and the wealth of historical research consolidating the meaning of the EIC metric in the pathogenesis of diabetes and the metabolic syndrome. 
By merit of the outcomes of this validation study, DISTq could occupy a low-cost niche in the spectrum of available insulin sensitivity tests. Currently, the homeostasis model assessment (HOMA) is often used in research applications where a low cost and intensity measurement of SI is acceptable []. The most frequently used form of HOMA requires a single sample, and is thus much less intense than DISTq. However, the true HOMA protocol requires three blood samples taken on three subsequent days []. Returning to the clinician for repeated blood tests could be considered more burdensome for the participant than the 30-minute DISTq protocol. The DISTq to EIC correlations (R=0.75-0.80) were also in the top end of those reported between the EIC and the HOMA (R=0.51 to 0.80)  ADDIN EN.CITE []. The correlation between the EIC and the HOMA found in this study was R=0.60. The original HOMA sensitivity metrics were derived via a simple function. However, the more accurate HOMA2 metric requires lookup charts or a freely available program [].
The Matsuda index requires a two-hour protocol and four insulin samples to yield a metric that correlates to the clamp at R=0.69-0.74  ADDIN EN.CITE [, ] (including this present study). The DISTq protocol is 30 minutes and does not require insulin samples. However, in contrast to DISTq, the OGTT protocol required to calculate the Matsuda index does not need to be undertaken by someone qualified to administer insulin. Thus, the relative clinical intensity of the tests is ambiguous and dependent on the particular constraints of the situation.
The iterative DISTq parameter identification process outlined in Figure 1 could be difficult for clinical groups that lack specific computational or numerical expertise. Hence, to overcome this barrier to uptake, the authors have developed a stand-alone computational program that can process input glucose data from the DISST protocol to yield SI values. The software will be made freely available upon request to the authors. Overall, DISTq may be considered a suitable alternative to HOMA in applications that require more robust SI measurement accuracy or when immediate results may be considered an advantage. 
The participant that consumed a lot of sugary drink highlights the limitations of this type of a-posteriori methodology. In particular, the participant’s first phase insulin response seems likely to have adapted to cope with the frequent and sudden influx of glucose []. C-peptide measurements taken during the clinical trial (but not used to evaluate DISTq SI) showed that the participant’s first phase insulin secretion response was 2.8U. This was well above upper quartile of the cohort first phase responses (1.10U) and the DISTq estimated secretion rate for this participant (0.46U). The DISTq equations that predict insulin secretion as a function of SI significantly underestimated the insulin response of this participant and SI was overestimated. Upon recruitment of this participant, it was suspected that DISTq would greatly over-estimate their SI. However, due to the recruitment criteria of the study the test was undertaken and the expected outcome was observed. This result implies that individuals with suspected irregularities in insulin pharmacokinetics (other than IGT) should either undergo a test that incorporates insulin assays, or their DISTq results should be interpreted with scepticism. However, the high correlation between the DISTq and EIC found in this cohort that ranged from very insulin sensitive to very insulin resistant individuals shows that the methodology is relevant and precise for a wide range of physiologies.
V.	Conclusions
By formulating a model of glucose and insulin dynamics that defines insulin sensitivity as the only variable to fit glucose decay, practical model identifiability was greatly improved. This improvement in identifiability effectively allowed massive reductions in the cost of the clinical protocol required to gather the requisite data to measure insulin sensitivity. The a-posteriori method relies on representative insulin pharmacokinetic equations to be used, but was successful for 49 of 50 subjects in this study. DISTq outperforms other low-cost insulin sensitivity tests and illustrates the potential for practical model identifiability methodologies to direct and improve clinical outcomes.
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